Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: A scoping review
FC Gialaim Purcino dos Reis, AG Menêses… - Revista da Escola de …, 2023 - SciELO Brasil
Objective: To map topical interventions used to prevent hand-foot syndrome in cancer
patients undergoing antineoplastic therapy. Method: This is a scoping review reported in …
patients undergoing antineoplastic therapy. Method: This is a scoping review reported in …
Intervenções tópicas para prevenção de síndrome mão-pé decorrente de terapia antineoplásica: revisão de escopo
FC Gialaim Purcino dos Reis, AG Menêses… - Revista da Escola de …, 2023 - SciELO Brasil
Objective: To map topical interventions used to prevent hand-foot syndrome in cancer
patients undergoing antineoplastic therapy. Method: This is a scoping review reported in …
patients undergoing antineoplastic therapy. Method: This is a scoping review reported in …
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish …
P Soria-Chacartegui, G Villapalos-García… - Pharmaceutics, 2021 - mdpi.com
Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity.
Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD …
Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD …
[HTML][HTML] Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with …
V Sapena, M Iavarone, L Boix, F Facchetti… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Dermatologic adverse events (DAEs) are associated with a better outcome
in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent …
in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent …
Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX)
P Martin, D Botsen, M Brugel, E Bertin, C Carlier… - Nutrients, 2022 - mdpi.com
In the FIGHTDIGO study, digestive cancer patients with dynapenia experienced more
chemotherapy-induced neurotoxicities. FIGHTDIGOTOX aimed to evaluate the relationship …
chemotherapy-induced neurotoxicities. FIGHTDIGOTOX aimed to evaluate the relationship …
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
P Villalvazo, B Marzal-Alfaro, P García-Alfonso… - Journal of Personalized …, 2021 - mdpi.com
Dihydropyrimidine dehydrogenase deficiency is a major cause of severe fluoropyrimidine-
induced toxicity and could lead to interruption of chemotherapy or life-threatening adverse …
induced toxicity and could lead to interruption of chemotherapy or life-threatening adverse …